Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week
...r Pharmaceuticals Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar((R)) Gel (repository corticotropin injection) and Doral((R)) (quazepam tablets, USP). Acthar is an injectable drug that is approved for the treatment of certain disorders with an inflam...Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
...crine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in men's and women's health. corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS The CRF collaboration between Neurocrine and GSK has identified mul...Yerkes researchers create animal model of chronic stress
...ber of behavioral changes and physical health problems, including anxiety, depression and infertility." Via the animal model, the researchers found corticotropin releasing factor (CRF) is a key neurohormone involved in stress response. Wilson explains, "CRF is located in several different brain regions, serving...Rat Study Gets at Root of Nicotine Addiction
...t to better drugs that can help smokers kick the habit. In rats, chronic nicotine use recruits a major brain stress system -- the extrahypothalamic corticotropin releasing factor (CRF) system. This contributes to continued nicotine use by exacerbating anxiety and craving whenever nicotine is withdrawn, the rese...Neurocrine Biosciences Reports First Quarter 2008 Results
...Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health. corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS The CRF collaboration between Neurocrine and GSK has identified multiple...Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
...RH antagonists in treating other hormone-dependent diseases in Men's and Women's Health. Partnership discussions are ongoing for our GnRH program. corticotropin Releasing Factor (CRF1) Receptor Antagonists in Mood Disorders and IBS. -- GSK has recently completed a Phase II "proof of concept" clinical trial...How the brain learns to become addicted
...t of behaviors associated with drug-craving in human addicts. The latest findings follow an earlier discovery by the same group that another molecule, corticotropin releasing factor (CRF), acts similarly. Such adaptations are believed to create a need that is far more compelling than the simple memory of drug-i...Neurocrine Biosciences Reports First Quarter 2009 Results
...ny continues to investigate the potential of certain GnRH antagonists in treating other hormone-dependent diseases in men's and women's health. corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS The CRF collaboration between Neurocrine and GSK has identified mul...Neurocrine Biosciences Reports Third Quarter 2008 Results
...Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health. corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS The CRF collaboration between Neurocrine and GSK has identified multiple...Neurocrine Biosciences Reports Second Quarter 2008 Results
...Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in Men's and Women's Health. corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS The CRF collaboration between Neurocrine and GSK has identified multiple...